Frank Sinicrope

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 119:2765-70. 2013
  2. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  3. pmc Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic and North Central Cancer Treatment Group, Rochester, Minnesota, USA
    Cancer 119:1528-36. 2013
  4. pmc Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications
    Frank A Sinicrope
    Mayo Cancer Center, Rochester, MN, USA
    Clin Cancer Res 18:1506-12. 2012
  5. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
  6. pmc DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 7:174-7. 2010
  7. pmc Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients
    Frank Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 116:1691-8. 2010
  8. pmc Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma
    Frank A Sinicrope
    Miles and Shirley Fiterman Digestive Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 137:1270-9. 2009
  9. pmc Clinical implications of microsatellite instability in sporadic colon cancers
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Oncol 21:369-73. 2009
  10. ncbi request reprint Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2
    Frank A Sinicrope
    Division of Gastroenterology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 4:1475-83. 2005

Research Grants

Detail Information

Publications54

  1. pmc Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 119:2765-70. 2013
    ..We used a mutation-specific antibody to examine mutant BRAFV600E protein expression and its concordance with BRAFV600E mutation data...
  2. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  3. pmc Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic and North Central Cancer Treatment Group, Rochester, Minnesota, USA
    Cancer 119:1528-36. 2013
    ..Although obesity is an established risk factor for developing colon cancer, its prognostic impact and relation to patient sex in colon cancer survivors remains unclear...
  4. pmc Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications
    Frank A Sinicrope
    Mayo Cancer Center, Rochester, MN, USA
    Clin Cancer Res 18:1506-12. 2012
    ..The ability to identify deficient MMR has important implications for patient management, and it holds promise for therapeutic exploitation and for the development of novel therapeutics...
  5. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
    ..Although the importance of obesity in colon cancer risk and outcome is recognized, the association of body mass index (BMI) with DNA mismatch repair (MMR) status is unknown...
  6. pmc DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 7:174-7. 2010
    ..Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer...
  7. pmc Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients
    Frank Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 116:1691-8. 2010
    ..The authors developed models to predict MMR deficiency in sporadic colon cancer patients using routine clinical and pathological data...
  8. pmc Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma
    Frank A Sinicrope
    Miles and Shirley Fiterman Digestive Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 137:1270-9. 2009
    ..We investigated whether the intratumoral densities of FoxP3(+) and effector CD3(+) lymphocytes are associated with prognosis of patients with colon cancer...
  9. pmc Clinical implications of microsatellite instability in sporadic colon cancers
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Oncol 21:369-73. 2009
    ..To review data demonstrating the prognostic and predictive impact of microsatellite instability (MSI) in human colon carcinomas...
  10. ncbi request reprint Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2
    Frank A Sinicrope
    Division of Gastroenterology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 4:1475-83. 2005
    ..Together, these data indicate that HA14-1 or TRAIL can enhance sulindac sulfide-induced apoptosis and represent novel strategies for circumventing Bcl-2-mediated apoptosis resistance in human colon cancer cells...
  11. pmc Prognostic impact of bim, puma, and noxa expression in human colon carcinomas
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 14:5810-8. 2008
    ..Expression of these proteins in colon cancer patients may account for differences in recurrence and survival rates...
  12. ncbi request reprint Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 131:729-37. 2006
    ..Given that high-frequency MSI (MSI-H) and diploidy are correlated, we determined whether they are independent prognostic variables...
  13. pmc Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Guggenheim 10 11C, 200 1st Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 14:4128-33. 2008
    ..We determined if expression of these proteins in colon cancers may account for differences in patient survival...
  14. ncbi request reprint Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients
    Frank A Sinicrope
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Epidemiol Biomarkers Prev 13:920-7. 2004
    ....
  15. ncbi request reprint Role of cyclooxygenase-2 in colorectal cancer
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Metastasis Rev 23:63-75. 2004
    ..Additionally, evidence supporting the role of NSAIDs and selective COX-2 inhibitors for the prevention and treatment of human colorectal cancer is reviewed...
  16. pmc Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic and Mayo Cancer Center, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Future Oncol 7:467-74. 2011
    ..The focus of this article is on the MMR phenotype and its prognostic and predictive implications for the management of patients with colorectal cancer...
  17. ncbi request reprint Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Int J Cancer 120:1232-8. 2007
    ....
  18. pmc DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Natl Cancer Inst 103:863-75. 2011
    ..We determined the association of MMR status with colon cancer recurrence and examined the impact of 5-fluorouracil (FU)-based adjuvant therapy on recurrence variables...
  19. doi request reprint Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia
    Frank A Sinicrope
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Prev Res (Phila) 4:829-39. 2011
    ..DFMO suppressed mucosal polyamines and modulated genes that may be mechanistically related to its chemopreventive effect. Further study of DFMO for the chemoprevention of esophageal cancer in BE patients is warranted...
  20. pmc Obesity is an independent prognostic variable in colon cancer survivors
    Frank A Sinicrope
    Divisions of Oncology and Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 16:1884-93. 2010
    ..Obesity is associated with an increased risk of colon cancer. However, the influence of body mass index (BMI) on the prognosis of colon cancer survivors and its relationship to gender remains unknown...
  21. ncbi request reprint Thymidylate synthase expression in colon carcinomas with microsatellite instability
    Frank A Sinicrope
    Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:2738-44. 2006
    ..Given that thymidylate synthase (TS) is inhibited by 5-FU, we studied the relationship between MSI and TS expression, and the prognostic effect of these and other markers (i.e., p53 and 17p allelic imbalance)...
  22. pmc Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
    Daniel J Sargent
    Division of Biomedical Statistics and Informatics, Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3219-26. 2010
    ..We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer...
  23. ncbi request reprint Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells
    Yunjie Sun
    Department of Gastrointestinal Medicine and Nutrition, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 62:6323-8. 2002
    ..COX-2-mediated up-regulation of Bcl-2 suggests a potential mechanism for reduced apoptotic susceptibility...
  24. ncbi request reprint Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells
    Frank A Sinicrope
    Divisions of Oncology, Gastroenterology and Hepatology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA sinicrope frank2mayo edu
    Clin Cancer Res 10:8284-92. 2004
    ..We determined the effect of ectopic Bcl-2 expression on TRAIL-induced apoptosis and whether the small molecule Bcl-2 inhibitor, HA14-1, could increase TRAIL sensitivity...
  25. ncbi request reprint Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells
    Ximing Tang
    Department of Gastrointestinal Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:4903-8. 2002
    ..In summary, modulation of DR-5 and Bcl-2 levels by COX-2 attenuates TRAIL-induced apoptosis and represents a novel mechanism of intrinsic drug resistance in human colon cancer cells...
  26. ncbi request reprint Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells
    Yunjie Sun
    Division of Gastroenterology Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 4:51-9. 2005
    ..Selective inhibitors of these MAPKs potentiate apoptosis induction by this NSAID, suggesting a novel strategy for the prevention or treatment of colorectal cancer...
  27. pmc BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells
    Shengbing Huang
    Miles and Shirley Fiterman Center for Digestive Diseases and Division of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 68:2944-51. 2008
    ..These findings suggest a novel strategy to enhance cross-talk between the extrinsic and intrinsic apoptotic pathways to improve therapeutic efficacy against pancreatic cancer...
  28. pmc Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells
    Shengbing Huang
    Divisions of Oncology and Gastroenterology, Fiterman Center for Digestive Diseases and Mayo Cancer Center, Mayo Clinic, Rochester, MN, USA
    Autophagy 6:256-69. 2010
    ..In conclusion, celecoxib induces apoptosis and autophagy that can both be potentiated by ABT-737. Inhibition of autophagy was shown to enhance apoptosis, suggesting a novel therapeutic strategy against colon cancer...
  29. ncbi request reprint Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells
    Shigeru Tatebe
    Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biochem Biophys Res Commun 290:1427-33. 2002
    ....
  30. ncbi request reprint A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker
    Dory Sample
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:275-9. 2002
    ..No adverse events occurred in this short-term study. The 81-mg daily aspirin dose suppressed PGE(2) levels to an equivalent extent as did the 650-mg dose and supports the use of this dose for chemoprevention trials...
  31. ncbi request reprint Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers
    Frank A Sinicrope
    Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 101:2818-25. 2006
    ..Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases...
  32. ncbi request reprint PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells
    Bonnie H Y Yeung
    Division of Gastroenterology, Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:11923-32. 2006
    ..Caspase-2 activation regulates PS-341-induced mitochondrial depolarization and apoptosis, suggesting that caspase-2 can serve as a link between lysosomal and mitochondrial permeabilization...
  33. pmc The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection
    Harry H Yoon
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:1080-9. 2010
    ..To identify and describe clinicopathologic prognostic factors in patients with esophageal adenocarcinoma who underwent surgical resection with curative intent...
  34. ncbi request reprint N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer
    Steven R Alberts
    Department of Medical Oncology, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:211-3. 2005
  35. ncbi request reprint HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors
    Elizabeth Half
    Department of Gastrointestinal Medicine and Nutrition University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 108:540-8. 2004
    ..Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation...
  36. pmc Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
    Shengbing Huang
    Divisions of Oncology and Gastroenterology Hepatology, Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 9:742-50. 2010
    ..These data indicate that targeting STAT3 may enhance treatment efficacy against pancreatic cancer...
  37. ncbi request reprint Advances in chemotherapy for colorectal cancer
    Dirk M Bernold
    Division of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Clin Gastroenterol Hepatol 4:808-21. 2006
    ..This review presents an update of the current approach to colon and rectal cancer treatment, highlighting recent chemotherapeutic advances in the management of these highly prevalent malignancies...
  38. ncbi request reprint Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells
    Elizabeth Half
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Lett 251:237-46. 2007
    ..Cooperative inhibition of cell growth by EGFR and ErbB-2 blockade suggests the therapeutic potential of targeting multiple ErbB receptors...
  39. pmc Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737
    Kenji Okumura
    Miles and Shirley Fiterman Center for Digestive Diseases and Division of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:8132-42. 2008
    ..We determined the effects of ABT-737, a small-molecule inhibitor of Bcl-2/Bcl-xL but not Mcl-1, on apoptosis induction alone and in combination with CPT-11 and explored mechanisms underlying their cooperativity...
  40. ncbi request reprint Chemoprevention of colorectal cancer
    Karin Gwyn
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Gastroenterol 97:13-21. 2002
    ..Chemopreventive strategies, if effective, offer the promise of producing a paradigm shift in our current approach to colorectal cancer...
  41. ncbi request reprint Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
    Sharlene Gill
    Division of Oncology, Mayo Clinic and Mayo College of Medicine, Rochester, MN, USA
    Semin Oncol 32:24-34. 2005
    ..In this review, the current status of CRC chemoprevention will be discussed, including the available evidence for selected pharmacologic and nonpharmacologic agents, particularly among high-risk populations...
  42. pmc BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells
    Shengbing Huang
    Miles and Shirley Fiterman Center for Digestive Diseases and Division of Oncology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin Cancer Res 15:150-9. 2009
    ..Obatoclax is a small-molecule antagonist of the BH3-binding groove of Bcl-2 proteins that may enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity and efficacy...
  43. ncbi request reprint Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Division of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Carcinog 45:447-54. 2006
    ..This review will focus on the role of COX-2 as a target for the prevention and treatment of human colorectal cancer...
  44. ncbi request reprint Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ
    Elizabeth Half
    Department of Gastrointestinal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:1676-81. 2002
    ..Our results suggest that nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer...
  45. pmc Autophagy modulation for cancer therapy
    Zhineng J Yang
    Mayo Clinic and Mayo Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Biol Ther 11:169-76. 2011
    ..Studies are ongoing to define optimal strategies to modulate autophagy for cancer prevention and therapy, and to exploit it as a target for anticancer drug discovery...
  46. ncbi request reprint Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial
    Dory A Sample
    Department of Gastrointestinal Medicine and Nutrition, The University of Texas M D Anderson Cancer Center, and The University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:281-5. 2002
    ..Continued post-study aspirin intake indicates an impact of study participation on a health-related behavior and underscores the importance of patient education to guide such decision-making...
  47. ncbi request reprint Radiation enteritis
    Mike M Bismar
    Department of Gastrointestinal Medicine and Nutrition, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 436, Houston, TX 77030, USA
    Curr Gastroenterol Rep 4:361-5. 2002
    ..Data indicate that radioprotectant agents have the potential to reduce intestinal mucosal injury and may be beneficial in reducing both acute and chronic side effects of radiotherapy...
  48. pmc A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells
    Rory L Smoot
    Division of Gastroenterologic and General Surgery, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:1960-9. 2010
    ..These data indicate that BH3 mimetics may also function as direct activators of Bax and induce cytotoxicity in cells not otherwise primed for cell death...
  49. ncbi request reprint Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma
    Shigeru Tatebe
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 97:21-7. 2002
    ..013) but not between gamma-GCSh and p53. Since gamma-GCS is a sensor of oxidative stress, these results are consistent with the notion that oxidative stress is associated with colorectal tumor progression...
  50. pmc The role of autophagy in cancer: therapeutic implications
    Zhineng J Yang
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 10:1533-41. 2011
    ..The role of autophagy and its regulation in cancer cells continues to emerge, and studies aim to define optimal strategies to modulate autophagy for therapeutic advantage...
  51. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  52. ncbi request reprint Insights into familial colon cancer: the plot thickens
    Frank A Sinicrope
    Clin Gastroenterol Hepatol 3:216-7. 2005
  53. ncbi request reprint Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci
    Greg Cohen
    Department of Medicine, University of Chicago, Illinois, USA
    Cancer Res 66:5656-64. 2006
    ..In summary, we have shown that ACF with up-regulated PCNA possess increased EGFR signaling components that likely contribute to the enhanced proliferative state of dysplastic-appearing ACF...
  54. ncbi request reprint Sporadic colorectal cancer: an infectious disease?
    Frank A Sinicrope
    Gastroenterology 132:797-801. 2007

Research Grants11

  1. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2009
    ....
  2. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2007
    ....
  3. Clinical Significance of Apoptosis in Colon Cancer
    Frank Sinicrope; Fiscal Year: 2006
    ..abstract_text> ..
  4. Polyphenon E for the Chemoprevention of Colorectal Cancer
    Frank A Sinicrope; Fiscal Year: 2010
    ..We will determine the effect of polyphenon E on precursor lesions of colorectal adenomas in patients at high risk of colorectal cancer. ..